Search the Newsreel

Investigation launched into Replimune after FDA doubts RP1 therapy data, shares drop 30%.

Johnson Fistel, PLLP has launched an investigation into Replimune Group, Inc. following a 30% drop in its share price. This decline occurred after the FDA released briefing documents that questioned the efficacy data for Replimune's RP1 therapy when combined with nivolumab, citing insufficient evidence …

Replimune Group, Inc. (REPL) Investors Who Suffered Losses

Johnson Fistel, PLLP is investigating Replimune Group, Inc. (NASDAQ: REPL) after its shares fell approximately 30% following the FDA's release of briefing documents raising concerns about Replimune’s investigational RP1 therapy. The FDA staff concluded that the IGNYTE trial was not adequate and well-controlled, and …

REPL Stock Clocks Worst Day In Over 3 Months — New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug

Shares of Replimune Group Inc (REPL) dropped 38% after the FDA released documents questioning the approval of its experimental cancer drug RP1. This marks the company's third attempt for accelerated approval in combination with nivolumab for advanced melanoma, following prior rejections due to an …

Repligen Corporation Stock 12‑Month Price Target Raised to $180.33, Implies 38% Upside

Analysts have raised Repligen Corporation's average 12-month price target to $180.33, up from $176.28. This new target suggests a potential upside of approximately 38% from its July 27 closing price. The consensus rating for RGEN remains a "Buy" among 22 analysts.

Repligen (RGEN) Held An M&A Call With BioLife Solutions.

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Repligen (NasdaqGS:RGEN) and BioLife Solutions recently held a merger and acquisition call. The discussion focused on potential combinations or partnerships in bioprocessing and cell and gene therapy …

Replimune Lead Drug Trial Data Deemed 'Not Interpretable' by FDA Staff

The FDA has deemed Replimune's mid-stage study data for its lead drug RP1 as "not interpretable," challenging the company's application for accelerated approval in combination with Bristol-Myers Squibb Co.'s Opdivo for advanced melanoma. Concerns were raised regarding the efficacy assessment from the single-arm IGNYTE …

Repligen Stock Rises As $1.5B BioLife Deal Targets EPS Boost

Repligen Corporation's stock rose significantly after announcing a $1.5 billion cash-and-stock deal to acquire BioLife Solutions. This acquisition aims to boost Repligen's EPS, adjusted margins, and revenue growth by expanding its bioprocessing footprint into the rapidly growing cell and gene therapy market with BioLife's …

Repligen (NASDAQ:RGEN) Rallies as Quality Stock Delivers Earnings Beat

Repligen (NASDAQ:RGEN) reported a significant earnings beat for Q2 2026, with non-GAAP EPS of $0.54 against an analyst consensus of $0.46, despite revenue being marginally below expectations. The stock surged over 75% in pre-market trading, recouping recent losses, as investors prioritized profitability improvements. The …

Replimune Stock Slides As Losses Deepen And Legal Risks Rise

Replimune Group Inc. (REPL) stock slid over 21% following clinical setbacks, deeper-than-expected losses, and a newly launched legal probe into alleged misstatements regarding its IGNYTE trial and RP1 program. The company reported a net loss of $3.38 per share, exceeding estimates, and faces a …

US FDA staff cast doubt on Replimune cancer drug’s benefit; shares slide

FDA staff reviewers have expressed doubts about the benefits of Replimune's skin cancer drug, RP1, citing flaws in the trial design that make it difficult to determine its effectiveness when used in combination with Bristol Myers Squibb's Opdivo. The FDA had previously declined approval …

Repligen Corp (RGEN) Q2 2026 Earnings Call Transcript

Repligen Corp announced strong Q2 2026 earnings, with 12% reported growth and 13% organic growth, leading to a raised full-year guidance for organic revenue and adjusted EPS. The company saw robust performance in proteins and analytics, with significant growth in APAC and emerging biotech. …

Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates

Repligen (RGEN) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.37 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Replimune (REPL) Slumps As Losses Mount And Legal Scrutiny Grows

Replimune Group Inc. (REPL) stock plunged by 18.66% amidst negative sentiment following its latest clinical trial outlook, wider-than-expected fiscal 2026 net losses, and a newly launched legal investigation into potential fiduciary duty breaches. Wedbush raised its price target from $6 to $9 but maintained …

Repligen Corp Bottom Line Declines In Q2

(RTTNews) - Repligen Corp (RGEN) announced a profit for second quarter that Drops, from last year The company's bottom line totaled $5.01 million, or $0.09 per share. This compares with $14.87 million, or $0.26 per share, last year. Excluding items, Repligen Corp reported adjusted …

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026 Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 11.9% year on year to $204.1 million. The company expects the full year's revenue to be around …

Repligen Reports Q2 2026 Revenue Growth, Raises Full-Year Organic Revenue and EPS Guidance

Repligen Corporation announced strong second-quarter 2026 financial results, with revenue reaching $204 million, marking a 12% year-over-year increase and 13% organic growth. Due to this performance and continued order momentum, the company has raised its full-year 2026 organic revenue growth guidance to 10.5%-13.5% and …

Repligen Reports Q2 2026: Revenue $204M, Adjusted EPS $0.54; Raises FY26 Guidance

Repligen reported strong second-quarter 2026 results with revenue of $204.1 million, a 12% year-over-year increase, and adjusted diluted EPS of $0.54. The company has raised its full-year 2026 guidance for organic revenue growth and adjusted diluted EPS, driven by continued order momentum and portfolio …

Repligen (NASDAQ:RGEN) Shares Gap Up Following Better-Than-Expected Earnings

Repligen to Acquire BioLife Solutions, Enhancing Cell Therapy Capabilities

Repligen Corporation announced its intent to acquire BioLife Solutions for approximately $1.5 billion, a strategic move aimed at strengthening Repligen's position in the rapidly expanding cell therapy market. The acquisition, valued at $31.00 per share, combines 64% Repligen stock and 36% cash, with the …

Replimune Group Inc (REPL) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Replimune Group Inc (REPL), detailing its volatility, financial risk, and investment risk metrics. It includes data such as Beta vs S&P 500 index, VaR, maximum drawdown, daily returns (best and worst), Sharpe Ratio, and various volatility measures …

Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy

Shares of Replimune fell significantly after FDA reviewers raised concerns about the efficacy of its lead cancer therapy, RP1, for advanced melanoma. The FDA's briefing documents questioned the methodology of Replimune's IGNYTE study, suggesting that the tumor response and duration may have been overstated, …

Repligen Corp (RGEN) Cash Flow

This article provides a detailed cash flow statement for Repligen Corp (RGEN), including quarterly and annual data for operating, investing, and financing activities. It also defines these cash flow types and provides key figures for RGEN, such as operating cash flow, capital expenditures, and …

Replimune Group Market Sentiment

This article provides an overview of the market sentiment for Replimune Group (REPL), highlighting analyst consensus, short interest, options flow, and recent insider activity. Key signals indicate a "Market Perform" consensus from analysts, a significant 49.9% short float that is trending downwards, and a …

Repligen (RGEN) Q2 Earnings: What To Expect

Repligen (RGEN) is set to report its Q2 earnings this Tuesday morning. Analysts expect the biopharma manufacturing company's revenue to grow 10.7% year over year, a slowdown from the previous year. The company beat revenue and EPS expectations last quarter, and analysts have generally …

REPL|Replimune Group Inc|Price:14.960|Chg%:-0.230

Replimune Group Inc. (REPL) is a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform. The company's lead product candidate, RP1, is being developed for advanced melanoma, and its pipeline also includes RP2 and RP3. This article provides an …

REPL|Replimune Group Inc|Price:12.060|Chg%:-0.800

Replimune Group Inc. (REPL) is a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform. The company's lead product candidate, RP1, is being developed for advanced melanoma, and its pipeline also includes RP2 and RP3. This article provides an …

Key deals this week: Stripe, IBM, Repligen, LXP Industrial Trust and more

[Business mergers and acquisitions concept. Share acquisition, asset business acquisition, amalgamation. Business review and development model. The abbreviation M and A on smart background, copy space.] Parradee Kietsirikul Here's a list of key deals reported across sectors this week: * Payments firm Stripe (STRIP …

Repligen Corporation Revenue Breakdown – NASDAQ:RGEN

This article details Repligen Corporation's revenue breakdown. Last year, the company generated $738.26 million USD, with its Filtration segment being the top performer at $402.79 million USD. North America was the largest regional contributor, accounting for $361.75 million USD.

REPL|Replimune Group Inc|Price:9.700|Chg%:-0.760

Replimune Group Inc. (REPL) is a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies using its proprietary RPx platform. The company's lead product candidate, RP1, is being developed for advanced melanoma, and its pipeline also includes RP2 and RP3. This article provides an …

Repligen Corp|Price:131.970|Chg%:-5.630

This article provides a company profile for Repligen Corporation (RGEN), a global life sciences company specializing in bioprocessing technologies. It details the company's focus areas, product portfolio, and key financial information. The article also lists company executives, their shareholdings, and institutional ownership data for …

Repligen Corp (RGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Repligen Corp (RGEN) by business segment and by region. For FY2025, filtration products were the largest segment, contributing 54.58% of revenue, while North America was the largest regional market at 49.00%. The data highlights the company's …

Replimune Group Inc (REPL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Replimune Group Inc (REPL), highlighting its major institutional holders and their proportion of shares. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent activities of top shareholders. Additionally, it lists several …

Repligen Corporation (RGEN) stock price, news, quote and history

This page provides a comprehensive overview of Repligen Corporation (RGEN) stock, including its current price, news, historical data, and financial analysis. It details the company's bioprocessing technologies and systems, product offerings, and recent financial performance, alongside analyst insights and comparisons with similar companies.

Replimune stock trades lower after cash burn and clinical updates shape outlook

Replimune Group Inc. (NASDAQ: REPL), an immuno-oncology company, is seeing its stock trade lower following financial results that show increasing operating losses despite a strong cash reserve and progressing clinical trials. The company's lead product candidate, RP1, is an oncolytic immunotherapy undergoing multiple clinical …

Repligen to Expand Cell Therapy Capabilities With BioLife Buyout

Repligen Corporation announced an agreement to acquire BioLife Solutions for approximately $1.5 billion, aiming to strengthen its position in the rapidly growing cell therapy market. This acquisition is expected to complement Repligen's existing solutions, add a high-margin consumables business, and be accretive to revenue …

Canaccord reiterates Hold on Repligen stock after BioLife deal

Canaccord Genuity has reiterated a Hold rating on Repligen Corp. with a $145.00 price target following Repligen's acquisition of BioLife Solutions for approximately $1.5 billion. While the acquisition is expected to be accretive to Repligen's financials and expand its presence in new modalities, Canaccord …